Water Level Observations in Mangrove Swamps During Two Hurricanes in Florida

Little is known about the effectiveness of mangroves in suppressing water level heights during landfall of tropical storms and hurricanes. Recent hurricane strikes along the Gulf Coast of the United States have impacted wetland integrity in some areas and hastened the need to understand how and to what degree coastal forested wetlands confer protection by reducing the height of peak water level. In recent years, U.S. Geological Survey Gulf Coast research projects in Florida have instrumented mangrove sites with continuous water level recorders. Our ad hoc network of water level recorders documented the rise, peak, and fall of water levels (6 0.5 hr) from two hurricane events in 2004 and 2005. Reduction of peak water level heights from relatively in-line gages associated with one storm surge event indicated that mangrove wetlands can reduce water level height by as much as 9.4 cm/km inland over intact, relatively unchannelized expanses. During the other event, reductions were slightly less for mangroves along a river corridor. Estimates of water level attenuation were within the range reported in the literature but erred on the conservative side. These synoptic data from single storm events indicate that intact mangroves may support a protective role in reducing maximum water level height associated with surge

Evidence supporting the recent origin and species status of the Timberline Sparrow

The Timberline Sparrow (Spizella taverneri), although originally described as a species, is currently classified as a subspecies of the more widespread Brewer\u27s Sparrow (S. breweri). We investigated the taxonomic status and recent evolutionary history of these species by comparison of both morphological and molecular characters. Morphometric comparisons using 6 external and 18 skeletal measurements show that S. taverneri specimens from two widely separated populations (Yukon and southwestern Alberta, Canada) are indistinguishable with respect to size yet are significantly larger (by 3%) than representatives of several breweri populations. Analysis of 1,413 base pairs of mitochondrial DNA (mtDNA) for 10 breweri and 5 taverneri samples representing widely scattered breeding populations revealed a maximum divergence among any breweri-taverneri pair of 0.21% and an overall average of 0.13%. In contrast, the average (± SE) pairwise distance among the other Spizella species is 5.7 ± 0.5%. We discovered that breweri and taverneri could be distinguished on the basis of a single, fixed nucleotide difference. Of an additional 11 taverneri and 8 breweri surveyed for this diagnostic site, a single bird (morphologically a taverneri) from northwest British Columbia did not sort to type. Overall, 18 of 18 breweri and 15 of 16 taverneri were diagnosable. We interpret these results to suggest that gene flow does not currently occur between these two forms and that each is on an independent, albeit recently derived, evolutionary course. The molecular data are consistent with theoretical expectations of a Late Pleistocene speciation event. We believe that for passerine birds, this is the first empirical validation of this widely accepted evolutionary model. The data presented corroborate plumage, vocal, and ecological evidence suggesting that these taxa are distinct. As such, we suggest that Spizella taverneri be recognized as a species

The taxonomic rank of Spizella taverneri: A response to Mayr and Johnson

Mayr and Johnson suggest that Spizella taverneri should be a subspecies of the biological species S. breweri, because it is possibly not reproductively isolated. We originally concluded that evidence from mitochondrial DNA sequences, habitat preferences, timing of breeding, vocalizations, and morphology supported the recognition of S. taverneri as a phylogenetic and biological species. Nothing in the commentary by Mayr and Johnson causes us to change that conclusion. We believe that it is probable that these two allopatric taxa are isolated. Contrary to Mayr and Johnson, we believe that more information is given by ranking S. taverneri as a species, because it reveals the fact that they are independently evolving taxa. The classification of Spizella should convey the sister-species status of S. taverneri and S. breweri, without regard for balancing the degree of sequence divergence among species, as suggested by Mayr and Johnson

Isolation of polymorphic microsatellites in the stemless thistle (Cirsium acaule) and their utility in other Cirsium species

The genus Cirsium includes species with both widespread and restricted geographical distributions, several of which are serious weeds. Nine polymorphic microsatellite loci were isolated from the stemless thistle Cirsium acaule. Eight were polymorphic in C. acaule, six in C. arvense and seven in C. heterophyllum. One locus monomorphic in C. acaule showed polymorphism in C. heterophyllum. The mean number of alleles per locus was 4.1 in C. acaule, 6.2 in C. arvense and 2.9 in C. heterophyllum. These nine loci were also amplified in C. eriophorum and C. vulgare, suggesting that these markers may be of use throughout the genus

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.

BackgroundSome trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States.MethodsREDUCE-IT randomized 8179 statin-treated patients with qualifying triglycerides ≥135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and ≤100 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary composite end point was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. A hierarchy was prespecified for examination of individual and composite end points.ResultsA total of 3146 US patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women and 9.7% were Hispanic. The primary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59-0.80]; P=0.000001); the key secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 0.57-0.83]; P=0.00008). All prespecified hierarchical end points were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%; HR, 0.66 [95% CI, 0.49-0.90]; P=0.007), myocardial infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56-0.93]; P=0.01), stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43-0.93]; P=0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55-0.90]; P=0.004); for all-cause mortality in the US versus non-US patients, Pinteraction=0.02. Safety and tolerability findings were consistent with the full study cohort.ConclusionsWhereas the non-US subgroup showed significant reductions in the primary and key secondary end points, the US subgroup demonstrated particularly robust risk reductions across a variety of individual and composite end points, including all-cause mortality.Clinical trial registrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01492361

Real-time single base specific detection of the Haemonchus contortus S168T variant associated with levamisole resistance using loop-primer endonuclease cleavage loop mediated isothermal amplification

Haemonchus contortus is a parasitic haematophagous nematode that primarily affects small ruminants and causes significant economic loss to the global livestock industry. Treatment of haemonchosis typically relies on broad-spectrum anthelmintics, resistance to which is an important cause of treatment failure. Resistance to levamisole remains less widespread than to other major anthelmintic classes, prompting the need for more effective and accurate surveillance to maintain its efficacy. Loop-primer endonuclease cleavage loop-mediated isothermal amplification (LEC-LAMP) is a recently developed diagnostic method that facilitates multiplex target detection with single nucleotide polymorphism (SNP) specificity and portable onsite testing. In this study, we designed a new LEC-LAMP assay and applied it to detect the levamisole resistance marker S168T in H. contortus. We explored multiplexing probes for both the resistant S168T and the susceptible S168 alleles in a single-tube assay. We then included a generic probe to detect the acr-8 gene in the multiplex assay, which could facilitate the quantification of both resistance markers and overall genetic material from H. contortus in a single step. Our results showed promising application of these technologies, demonstrating a proof-of-concept assay which is amenable to detection of resistance alleles within the parasite population, with the potential for multiplex detection, and point-of-care application enabled by lateral flow end-point detection. However, further optimisation and validation is necessary

N plus 3 Advanced Concept Studies for Supersonic Commercial Transport Aircraft Entering Service in the 2030-2035 Period

Boeing, with Pratt & Whitney, General Electric, Rolls-Royce, M4 Engineering, Wyle Laboratories and Georgia Institute of Technology, conducted a study of supersonic commercial aircraft concepts and enabling technologies for the year 2030-2035 timeframe. The work defined the market and environmental/regulatory conditions that could evolve by the 2030/35 time period, from which vehicle performance goals were derived. Relevant vehicle concepts and technologies are identified that are anticipated to meet these performance and environmental goals. A series of multidisciplinary analyses trade studies considering vehicle sizing, mission performance and environmental conformity determined the appropriate concepts. Combinations of enabling technologies and the required technology performance levels needed to meet the desired goals were identified. Several high priority technologies are described in detail, including roadmaps with risk assessments that outline objectives, key technology challenges, detailed tasks and schedules and demonstrations that need to be performed. A representative configuration is provided for reference purposes, along with associated performance estimates based on these key technologies

Zonal flow production in the L–H transition in Alcator C-Mod

Transitions of tokamak confinement regimes from low- to high-confinement are studied on Alcator C-Mod (Hutchinson et al 1994 Phys. Plasmas 1 1511) tokamak using gas-puff-imaging, with a focus on the interaction between the edge drift-turbulence and the local shear flow. Results show that the nonlinear turbulent kinetic energy transfer rate into the shear flow becomes comparable to the estimated value of the drift turbulence growth rate at the time the turbulent kinetic energy starts to drop, leading to a net energy transfer that is comparable to the observed turbulence losses. A corresponding growth is observed in the shear flow kinetic energy. The above behavior is demonstrated across a series of experiments. Thus both the drive of the edge zonal flow and the initial reduction of turbulence fluctuation power are shown to be consistent with a lossless kinetic energy conversion mechanism, which consequently mediates the transition into H-mode. The edge pressure gradient is then observed to build on a slower (1ms) timescale, locking in the H-mode state. These results unambiguously establish the time sequence of the transition as: first the peaking of the normalized Reynolds power, then the collapse of the turbulence, and finally the rise of the diamagnetic electric field shear as the L-H transition occurs. © 2014 IOP Publishing Ltd

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

BACKGROUND: In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These patients are at risk for not only first but also subsequent ischemic events. OBJECTIVES: Pre-specified analyses determined the extent to which icosapent ethyl reduced total ischemic events. METHODS: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated patients with triglycerides ≥135 and 40 and ≤100 mg/dl (median baseline of 75 mg/dl), and a history of atherosclerosis (71% patients) or diabetes (29% patients) to icosapent ethyl 4 g/day or placebo. The main outcomes were total (first and subsequent) primary composite endpoint events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) and total key secondary composite endpoint events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). As a pre-specified statistical method, we determined differences in total events using negative binomial regression. We also determined differences in total events using other statistical models, including Andersen-Gill, Wei-Lin-Weissfeld (Li and Lagakos modification), both pre-specified, and a post hoc joint frailty analysis. RESULTS: In 8,179 patients, followed for a median of 4.9 years, 1,606 (55.2%) first primary endpoint events and 1,303 (44.8%) subsequent primary endpoint events occurred (which included 762 second events, and 541 third or more events). Overall, icosapent ethyl reduced total primary endpoint events (61 vs. 89 per 1,000 patient-years for icosapent ethyl versus placebo, respectively; rate ratio: 0.70; 95% confidence interval: 0.62 to 0.78; p < 0.0001). Icosapent ethyl also reduced totals for each component of the primary composite endpoint, as well as the total key secondary endpoint events (32 vs. 44 per 1,000 patient-years for icosapent ethyl versus placebo, respectively; rate ratio: 0.72; 95% confidence interval: 0.63 to 0.82; p < 0.0001). CONCLUSIONS: Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events. (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial [REDUCE-IT]; NCT01492361)